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Background/aim: To compare plasma vitamin D concentrations among patients with normal cognitive function (control group), mild
cognitive impairment (MCI), and Alzheimer disease (AD).
Materials and methods: In total, 158 patients with AD, 228 patients with MCI, and 603 control subjects were included. Plasma levels
of 25-hydroxyvitamin D were measured after comprehensive geriatric assessment and compared among groups. SPSS 15.0 was used for
statistical analysis.
Results: Mean levels of 25-hydroxyvitamin D were significantly different among the 3 groups of AD patients, MCI patients, and controls
(P < 0.001). Post hoc analysis revealed that the levels were significantly lower in the MCI group than the control group (P = 0.002)
and significantly lower in the AD group than the control group (P = 0.003). Multivariate analysis showed that age (OR: 1.070, 95% CI:
1.025–1.116, P = 0.002), instrumental activities of daily living score (OR: 0.920, 95% CI: 0.850–0.995, P = 0.037), 25-hydroxyvitamin
D level (OR: 0.959, 95% CI: 0.932–0.987, P = 0.004), and diabetes mellitus (OR: 2.476, 95% CI: 1.153–5.319, P = 0.020) were factors
independently associated with AD.
Conclusion: This study demonstrated that there is a correlation between plasma 25-hydroxyvitamin D levels and cognitive functions.
Key words: Vitamin D status, Alzheimer disease, cognitive dysfunction, minimal cognitive impairment

1. Introduction
Alzheimer disease (AD) is the most common form
of dementia in geriatric patients and progresses with
progressive memory loss and cognitive dysfunction (1,2).
Vitamin D is one of the essential hormones for homeostasis,
muscle strength, and innate immunity. It maintains many
physiological functions (3). Vitamin D deficiency is
associated with increased risk of several types of cancer,
autoimmune diseases, and cardiovascular disorders (4). In
the last decade, experimental studies demonstrated that
vitamin D is the ‘forgotten neurosteroid’ hormone required
for normal brain regulation and development (5). Vitamin
D plays an important role in neurodegenerative disorders
with pathogenesis related to neurotrophin, inducible nitric
oxide synthesis, glutathione and monoamine synthesis,
and apoptosis (6).
Low serum 25-hydroxyvitamin D levels are frequently
determined among geriatric patients with a prevalence
reaching 90% (7). Hypovitaminosis D is also highly
* Correspondence: drcemalk@yahoo.com.tr

associated with cognitive disorders, especially with
advanced-stage dementia (8,9). Mild cognitive impairment
(MCI) is the early stage of cognitive dysfunction, causing
memory complaints without a disturbance in daily life
activities, and is encountered with an increasing prevalence
of AD (10). Although there are some studies examining the
relationship between cognitive decline and vitamin D levels,
to the best of our knowledge, it is not well documented and
there is no consensus in the literature about the relationship
between serum 25-hydroxyvitamin D level and patients’
cognitive status. The aim of this current study is to measure
vitamin D concentrations and evaluate its association with
cognitive functions among 3 groups of patients with normal
cognitive function, MCI, and AD.
2. Materials and methods
2.1. The participants and study design
A total of 989 subjects aged 65 years and older who were
admitted to our outpatient clinic of geriatric medicine
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were included in this cross-sectional study. To evaluate
the participants, comprehensive geriatric assessment,
including the evaluation of medical history, physical
examination, and assessment scales such as the MiniMental State Examination (MMSE) (11), Activities of
Daily Living (ADL) (12), Mini Nutritional Assessment
Short Form (MNA-SF) (13), and Instrumental Activities
of Daily Living (IADL) (14) scales, was performed. DSMIV (15) and NINCDS-ADRDA (16) criteria were used for
the diagnosis of AD. Neuroimaging by using magnetic
resonance was performed for patients before AD diagnosis
in order to exclude reversible causes of dementia. The
patients with AD had a score of 1 or higher according to
Clinical Dementia Rating (CDR) Scale (17). Peterson’s
criteria were used for MCI diagnosis (18–20). The
participants of the control group with normal cognitive
function had been selected from patients meeting the
following criteria: age- and sex-matched to the AD and
MCI groups, no memory complaints, normal test scores
of MMSE and clock drawing tests (21), not meeting the
criteria for MCI or AD, and score of 0 on the CDR Scale.
The medical histories of the patients were evaluated.
Presence of hypertension, diabetes mellitus, coronary
artery diseases (history of angina pectoris, previous heart
attack, myocardial infarction, and documented coronary
artery disease by coronary angiography), other systemic
chronic diseases, and history of operations were noted.
Body mass index (BMI) was calculated by the formula of
body weight/height2. Medications received by the patients
were noted, including medications containing calcium or
vitamin D. All the participants underwent standardized
clinical examination.
Patients with diagnosis of renal failure, liver failure,
and malignant diseases were excluded from the study.
This study was approved by the Local Ethics Committee
of Hacettepe University Faculty of Medicine and was
conducted in accordance with the Declaration of Helsinki.
The participants were divided into 3 groups: AD
patients, MCI patients, and patients with normal cognitive
function (control group).
2.2. Laboratory examination
Routine laboratory tests were performed in order to evaluate
the patients and exclude reversible causes of dementia.
Blood samples were collected after an 8-h fast. Routine
hemogram laboratory tests including hemoglobin, white
blood cell count, platelet levels, and biochemical analyses
were performed. Biochemical tests consisted of vitamin
B12, folic acid, total protein and albumin, fasting plasma
glucose (FPG), creatinine, alanine aminotransferase (ALT),
aspartate aminotransferase, thyroid stimulating hormone,
alkaline phosphatase, gamma glutamyl transferase, total
cholesterol (TC), high density lipoprotein, triglyceride,
low density lipoprotein, and C-reactive protein (CRP)
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levels. Plasma 25-hydroxyvitamin D levels were assessed
by high-performance liquid chromatography. The plasma
vitamin D levels were measured using the LC-20AT
solvent delivery unit (Shimadzu Corporation, Kyoto,
Japan), and the ImmuChrom ELISA kit (ImmuChrom
GmbH, Heppenheim, Germany) was used for analysis
of plasma vitamin D levels. The intraassay coefficients of
variation (CVs) were 2.6% (control value: 22.6 ng/mL) and
1.5% (control value: 41.9 ng/mL), the interassay CVs were
4.0% (control value: 21.6 ng/mL) and 3.6% (control value:
42.2 ng/mL), and the kit’s detection limit and upper limit
of linearity were 2.3 ng/mL and 500 ng/mL, respectively.
2.3. Statistical analysis
The distribution of continuous variables was assessed
by visual and analytic methods such as histogram,
Kolmogorov–Smirnov or Shapiro–Wilks tests, and
probability plots. Normally distributed continuous
variables are shown as mean ± standard deviation (SD),
while skew-distributed continuous variables are shown as
median (minimum–maximum). Categorical parameters
are shown as number of patients and frequencies.
Pearson’s chi-square test was used for comparing
categorical variables. Comparisons of normally distributed
continuous variables among the 3 groups were evaluated
by one-way ANOVA test. To determine the homogeneity
of variances, the Levene test was used. The Tamhane test
and post hoc Tukey tests were applied in accordance with
homogeneity of variances. The Kruskal–Wallis test was
used for comparing ADL and CRP levels. Pearson or
Spearman tests were used for the correlation analysis of
numerical variables. To define the independent related
factors for AD, logistic regression analysis was performed.
Values of P < 0.05 were considered statistically significant.
For the statistical analyses, SPSS 15.0 was used.
3. Results
A total of 158 patients with AD, 228 patients with MCI,
and 603 patients with normal cognitive function were
included in this study. Mean age ± SD of subjects was 71.4
± 6.3 years in patients with normal cognitive function,
71.7 ± 5.7 years in MCI patients, and 75.2 ± 6.7 years in
AD patients (P < 0.001), while 229 (38%) of the control
group, 61 (26.8%) of the MCI group, and 63 (39.9%) of the
AD group were male (P = 0.005). Demographic properties,
geriatric assessment test scores, laboratory parameters,
and comorbidities of the study population are presented
in Table 1.
The mean ± SD of 25-hydroxyvitamin D levels was
significantly different among the 3 groups (P < 0.001)
(Figure). After post hoc analysis, significant differences
were found between MCI and control groups (20.68 vs.
23.74 ng/mL, P = 0.002) and AD and control groups (20.29
vs. 23.74 ng/mL, P = 0.003). There was no significant
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Table 1. Demographic properties, geriatric assessment test scores, laboratory parameters, and comorbidities of the study population.
Parameters*

Control (n = 603)

MCI (n = 228)

AD (n = 158)

P

Age, years

71.4 ± 6.3

71.7 ± 5.7

75.2 ± 6.7

<0.001

Sex (male)

229 (38.0%)

61 (26.8%)

63 (39.9%)

0.005

BMI, kg/m2

27.30 ± 4.06

26.81 ± 4.15

26.85 ± 3.45

0.336

MMSE score

26.71 ± 3.65

25.97 ± 3.69

21.51 ± 7.38

<0.001

ADL score

0.00 (0.00–24.00)

1.00 (0.00–8.00)

0.00 (0.00–27.00)

0.644

IADL score

14.64 ± 3.00

14.46 ± 3.24

13.50 ± 3.97

0.016

MNA-SF score

12.29 ± 2.16

12.47 ± 1.81

11.41 ± 3.01

0.002

Vitamin D, ng/mL

23.74 ± 12.35

20.68 ± 11.07

20.29 ± 9.34

<0.001

HGB, g/dL

13.82 ± 1.34

13.72 ± 1.22

13.73 ± 1.29

0.552

WBC, /µL

6741.10 ± 2049.06

6685.42 ± 1916.61

6782.21 ± 1868.60

0.890

PLT, /µL

252,919.40 ± 70,605.90

256,204.40 ± 70,579.88

249,309.70 ± 85,354.91

0.662

CRP, mg/dL

0.37 (0.10–20.31)

0.35 (0.10–20.10)

0.34 (0.10–12.00)

0.649

Vitamin B12, pg/mL

323.58 ± 183.89

338.93 ± 113.20

347.36 ± 139.03

0.342

Folate, ng/mL

11.84 ± 5.24

11.91 ± 5.58

10.79 ± 5.35

0.079

BUN, mg/dL

18.64 ± 5.64

18.25 ± 6.06

19.66 ± 6.15

0.062

Creatinine, mg/dL

0.92 ± 0.27

0.87 ± 0.23

0.96 ± 0.30

0.004

Total protein, g/dL

7.53 ± 0.47

7.52 ± 0.47

7.45 ± 0.56

0.219

Albumin, g/dL

4.23 ± 0.33

4.23 ± 0.34

4.18 ± 0.36

0.188

FPG, mg/dL

109.19 ± 42.27

105.40 ± 38.15

97.57 ± 24.61

0.005

TC, mg/dL

208.17 ± 45.77

215.88 ± 46.20

203.23 ± 45.37

0.021

TG, mg/dL

142.21 ± 72.22

142.73 ± 81.04

134.57 ± 66.32

0.478

HDL, mg/dL

55.53 ± 14.82

57.90 ± 14.14

56.78 ± 14.74

0.108

LDL, mg/dL

123.26 ± 38.65

125.61 ± 40.96

119.61 ± 36.30

0.333

TSH, µIU/mL

1.54 ± 1.26

1.54 ± 1.15

1.63 ± 1.24

0.702

ALT, U/L

19.66 ± 8.89

20.19 ± 9.15

17.89 ± 7.76

0.034

AST, U/L

21.92 ± 9.05

22.48 ± 8.56

22.03 ± 13.38

0.765

ALP, U/L

146.93 ± 82.43

147.93 ± 84.76

143.92 ± 85.79

0.893

GGT, U/L

25.78 ± 19.67

25.08 ± 21.18

22.30 ± 18.46

0.157

Season (summer)

361 (60.0%)

141 (62.1%)

79 (50.3%)

0.050

Vitamin D therapy

251 (41.60%)

85 (37.30%)

44 (31.90%)

0.085

HT

434 (72.20%)

170 (74.90%)

104 (67.10%)

0.246

DM

151 (25.10%)

58 (25.60%)

12 (7.60%)

<0.001

CAD

165 (25.10%)

52 (22.90%)

30 (19.20%)

0.072

MCI: Mild cognitive impairment, AD: Alzheimer disease, BMI: Body mass index, MMSE: Mini-Mental State Examination, ADL:
Activities of Daily Living, IADL: Instrumental Activities of Daily Living, MNA-SF: Mini-Nutritional Assessment Test-Short Form, HGB:
Hemoglobin, WBC: White blood cell, PLT: Platelet, CRP: C-reactive protein, BUN: Blood urine nitrogen, FPG: Fasting plasma glucose,
TC: Total cholesterol, TG: Triglyceride, HDL: High density lipoprotein, LDL: Low density lipoprotein, TSH: Thyroid-stimulating
hormone, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, ALP: Alkaline phosphatase, GGT: Gamma glutamyl
transferase, HT: Hypertension, DM: Diabetes mellitus, CAD: Coronary artery disease. *: Parameters with statistically significant
differences.
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P < 0.001

Figure. Plasma vitamin D levels (ng/mL) of the patients with AD,
MCI, and normal cognitive functions (20.29 ± 9.34 ng/mL, 20.68
± 11.07 ng/mL, and 23.74 ± 12.35 ng/mL, respectively). After
post hoc analysis, significant differences were found between
MCI and control groups (20.68 vs. 23.74 ng/mL, P = 0.002) and
AD and control groups (20.29 vs. 23.74 ng/mL, P = 0.003).

difference between patients with MCI and AD (P = 0.944).
The mean ± SD values of IADL score, MNA-SF scores, and
FPG, TC, and ALT levels were significantly lower while
creatinine was significantly higher in patients with AD
than in the control group. Frequency of diabetes mellitus
in AD patients was significantly lower than in the MCI and
control groups. The mean ± SD of vitamin D levels of male
patients was significantly higher than in female patients
(24.22 ± 11.42 vs. 21.46 ± 11.74 ng/mL, P < 0.001). The
number of male patients receiving vitamin D replacement
was lower than female patients [93 (26.9%) vs. 289 (45.9%),
P < 0.001].
Age, sex, MMSE score, IADL score, MNA-SF score,
diabetes mellitus rate, and 25-hydroxyvitamin D,
creatinine, FPG, TC, and ALT levels were significantly
different among the 3 groups in univariate analysis. All

of these parameters and the data on receiving vitamin
D supplements were put into equations for multivariate
analysis in order to find out the independent correlates of
AD. Multivariate regression analysis revealed that age (OR:
1.070, 95% CI: 1.025–1.116, P = 0.002), IADL score (OR:
0.920, 95% CI: 0.850–0.995, P = 0.037), 25-hydroxyvitamin
D level (OR: 0.959, 95% CI: 0.932–0.987, P = 0.004), and
diabetes mellitus (OR: 2.476, 95% CI: 1.153–5.319, P =
0.020) were independent correlates of AD. The results of
the multiple logistic regression analysis of the possible
correlates for AD are summarized in Table 2.
Correlation analysis between plasma vitamin D levels
and other biochemical parameters revealed that there
were no correlations between vitamin D levels and BMI
(P = 0.350, r = –0.036), blood urea nitrogen (P = 0.527,
r = –0.020), protein (P = 0.950, r = 0.002), albumin (P =
0.076, r = 0.057), triglyceride (P = 0.956, r = 0.002), low
density lipoprotein (P = 0.241, r = 0.038), very low density
lipoprotein (P = 0.396, r = 0.027), total cholesterol (P =
0.156, r = 0.045), thyroid-stimulating hormone (P = 0.975,
r = –0.001), CRP (P = 0.445 r = –0.026), and homocysteine
levels (P = 0.700, r = –0.013), but there were very weak
positive correlations between vitamin D levels and high
density lipoprotein (P = 0.043, r = 0.065), vitamin B12 (P =
0.006, r = 0.090), folate (P = 0.038, r = 0.067), uric acid (P <
0.001, r = 0.125), and creatinine (P = 0.002, r = 0.101) levels.
4. Discussion
In this cross-sectional study, we found that
25-hydroxyvitamin D levels of patients with MCI and
AD were significantly lower than those of patients with
normal cognitive function and 25-hydroxyvitamin D
was independently related with AD. To the best of our
knowledge, this is the first study comparing these 3 groups
in the same setting.
During the last decade, vitamin D and its constructive
effects on the human body has been one of the big subjects
of debate and investigation. As it is a common deficiency
in the geriatric population, it is important to seek its
potential role in cognitive dysfunction. First, a systemic

Table 2. The results of the multiple logistic regression analysis of the possible correlates for AD.
Parameters

β

95% CI
Lower

Upper

Age

1.070

1.025

1.116

0.002

IADL

0.920

0.850

0.995

0.037

Vitamin D

0.959

0.932

0.987

0.004

DM

2.476

1.153

5.319

0.020

IADL: Instrumental Activities of Daily Living, DM: Diabetes Mellitus.
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review in 2009 revealed the association between cognitive
problems and vitamin D deficiency (22). In spite of gradual
incremental data regarding the association between
vitamin D deficiency and cognitive problems, to the best
of our knowledge it is still unclear whether serum vitamin
D level is associated with cognitive status and whether it
is significantly different in patients with normal cognitive
function, MCI, and AD. On the other hand, evidence
about only MCI in the literature is very weak. In one study,
Wilkins et al. (23) chose only the Short Blessed Test (SBT)
in order to compare patients, with only 60 MCI and normal
cognitive function patients, and they found a relationship
between vitamin D status and SBT score. A recent study
about patients with MCI and normal cognitive function
was done by Annweiler et al. (10), where 125 patients were
included in the Gait and Alzheimer Interaction Tracking
(GAIT) study and they were divided into 2 groups according
to their cognitive status: 95 of 125 were nondemented and
the remaining 43 patients had MCI. They reported that
25-hydroxyvitamin D levels were significantly lower (P
= 0.006) in MCI patients and logistic regression analysis
showed that higher vitamin D levels decreased the risk of
MCI. Our study also demonstrated that vitamin D levels
were significantly lower in 228 patients with MCI than in
603 patients with normal cognitive function (P = 0.001).
One of the strengths of our study is the high number of
patients analyzed.
Some genetic and nongenetic factors play roles
in the main pathogenesis of AD. AD is the end point
of degenerative and vascular processes. Progressive
neuronal damage causes gradual cognitive decline. This
multifactorial pathogenesis leads researchers to study
multitarget solutions. At this point, vitamin D is a recently
recognized popular multitarget neuroprotective agent.
Vitamin D has effects via its receptor (VDR) on neurons
in the way of crossing the blood brain barrier (24). In AD,
amyloid β-42 peptide aggregates in the extracellular space
as senile plaques. This process results in neuron death by
the neurotoxic effects of amyloid beta through oxidative
stress, inflammation, and excitotoxicity. Meanwhile,
amyloid plaques and oxidative stress increase the
phosphorylation of tau proteins controlled by the MAP
kinase enzyme. Thus, neurofibrillary tangles aggregate
and degeneration of neurons is reinforced (1). As a result,
both amyloid plaques and neurofibrillary tangles lead to
excessive calcium entry into neurons by glutamatergic
neuronal stimulation, causing necrosis and apoptosis (25).
Roles of vitamin D in the central nervous system include
its neurotrophic, neuroprotective, and neuromodulating
effects on those pathophysiologic mechanisms of AD (26).
Furthermore, an animal study indicated that vitamin D
usage increases the activity of choline acetyltransferase
in different parts of the rat brains. This study supports

the idea that hypothesis vitamin D may play a role on
acetylcholine pathway (27). Genetic factors are more
virgin fields of AD. Experimental studies shows that VDR
genotypes and gene polymorphism may have an essential
role in the neuroprotective effect of vitamin D (28).
The role of low levels of vitamin D as a vascular
risk factor may be another hypothesis underlying this
relationship. Recently, several studies demonstrated
that 25-hydroxyvitamin D may be a novel marker for
cardiovascular disease. Lower levels of 25-hydroxyvitamin
D were found to be associated with all causes of mortality
and higher myocardial infarction risk, whereas an increase
in its level protects against cardiovascular disease (29–31).
In the last decade, vascular factors have been shown to play
roles in AD. Various vascular changes, atherosclerosis, and
endothelial dysfunction were found to be linked to AD
(32,33). This vascular hypothesis may be the link between
AD and vitamin D. Another possible explanation for
the significant association between vitamin D status and
cognitive dysfunction was suggested in previous studies.
It was suggested that AD and similar degenerative diseases
may cause deprivation of feeding and sun exposure (4,8),
thus leading to vitamin D deficiency. However, our results
showing no significant difference in vitamin D levels
between MCI and AD patients effectively demonstrates
that vitamin D level may be low in patients without any
functional decline, as in MCI. This makes the hypotheses
of vitamin D acting as a neuroprotective agent and vitamin
D deficiency being a vascular risk factor more possible
mechanisms to explain this significant association.
In this study, we did not find a significant difference
between MCI and AD groups. It was previously shown that
continuous vitamin D deficiency is strongly associated with
the progression of cognitive decline, as from MCI to AD
(1). Diagnosis of MCI is still not clear enough. Different
diagnostic criteria are used in different studies. The most
feasible and most widely used criteria are the Peterson
criteria, which were used in our study for MCI diagnosis. On
the other hand, many of the patients with AD in the present
study were in the early stage; the percentage of moderate and
severe AD patients were very low. This pathophysiological
process might be the reason for not finding a significant
difference in vitamin D levels between MCI and AD
groups (34). Further studies including more patients with
moderate and severe dementia with longitudinal follow-up
are needed to further explain this point.
Most of the patients in the control, MCI, and AD
groups were female (n = 374 of 603, n = 167 of 228, and n
= 95 of 158, respectively). In spite of some studies (35–37)
showing that sex difference may have some effects on results,
others demonstrated no effect of sex on the association
of vitamin D status and cognitive functions (38). In our
study, although the number of patients receiving vitamin
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D therapy was lower in male patients, vitamin D level of
male patients was higher than that of female patients. This
difference may be due to the clothing habits of our female
patients. As the majority of them are covered, this may
interfere with exposure to sunlight. The recommended
vitamin D level in patients in order to prevent adverse
events is 30 ng/mL (39). In our study, the mean ± SD of
vitamin D level in the AD group was 20.29 ± 9.34 ng/mL.
Other independent correlates of AD were determined to
be age, diabetes mellitus, and IADL score. Advanced age is
a well-known contributing factor for AD (38,40). Diabetes
mellitus as a cardiovascular risk factor significantly and
independently increases risk for AD (41). IADL score is
one of the important cornerstones of dementia and its
progression also affects survival rates (42,43). The present
study also emphasized that independency in IADL has a
negative association with AD.

Our study has some potential limitations that should be
indicated. Initially, it was done in one center and probably
does not represent the general geriatric population.
The cross-sectional design of our study was the biggest
handicap, such that we may not determine causality.
Furthermore, some factors that may interfere with vitamin
D status, such as serum parathyroid hormone levels, the
proportion of dietary intake of vitamin D, and genetic
factors of VDR genotypes and polymorphism, were not
studied.
In conclusion, our study demonstrated that there is a
strong correlation between 25-hydroxyvitamin D levels
and cognitive functions. Further prospective studies
are required to explain this association. In addition,
randomized clinical trials are essential to understand
whether vitamin D treatment has an influence on
prevention and amelioration of AD or not.
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